Zivo Financial Statements From 2010 to 2026

ZIVO Stock  USD 10.75  0.25  2.38%   
Zivo Bioscience's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Zivo Bioscience's valuation are provided below:
Gross Profit
66.2 K
Market Capitalization
41.8 M
Enterprise Value Revenue
203.6353
Revenue
209 K
Earnings Share
(2.18)
We have found one hundred twenty available fundamental gauges for Zivo Bioscience, which can be analyzed and compared to other ratios and to its peers. Self-guided Investors are advised to confirm Zivo Bioscience's prevalent fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 5th of February 2026, Market Cap is likely to drop to about 1.5 M. In addition to that, Enterprise Value is likely to drop to about 1.8 M

Zivo Bioscience Total Revenue

148,573

Check Zivo Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zivo Bioscience's main balance sheet or income statement drivers, such as Interest Expense of 25.1 K, Other Operating Expenses of 16.3 M or Total Operating Expenses of 16.2 M, as well as many indicators such as Price To Sales Ratio of 563, Dividend Yield of 0.0 or Days Sales Outstanding of 5.61. Zivo financial statements analysis is a perfect complement when working with Zivo Bioscience Valuation or Volatility modules.
  
Build AI portfolio with Zivo Stock
Check out the analysis of Zivo Bioscience Correlation against competitors.
To learn how to invest in Zivo Stock, please use our How to Invest in Zivo Bioscience guide.

Zivo Bioscience Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities2.2 M2.3 M5.9 M
Very volatile
Accounts Payable725.7 K853.1 K801.1 K
Pretty Stable
Common Stock Shares Outstanding4.1 M3.9 M1.2 M
Slightly volatile
Other Stockholder Equity164.8 M156.9 M75.5 M
Slightly volatile
Total Liabilities2.4 M2.5 M7.5 M
Pretty Stable
Common StockK4.2 K86.9 K
Slightly volatile
Common Stock Total Equity498.7 K475 K263.4 K
Slightly volatile
Total Assets1.2 M1.9 M1.5 M
Slightly volatile
Other Current Liabilities1.9 M1.3 M2.2 M
Pretty Stable
Cash1.9 M1.8 M1.1 M
Slightly volatile
Cash And Short Term Investments1.9 M1.8 M1.1 M
Slightly volatile
Liabilities And Stockholders Equity1.2 M1.9 M1.5 M
Slightly volatile
Inventory5.3 K5.6 KK
Pretty Stable
Other Current Assets109.6 K104.4 K53.1 K
Slightly volatile
Total Current AssetsM1.9 M1.2 M
Slightly volatile
Short and Long Term Debt Total277.9 K292.5 K4.8 M
Pretty Stable
Short Term Debt150.9 K158.9 K2.8 M
Very volatile
Intangible Assets1.7 M1.6 M1.2 M
Slightly volatile
Other Liabilities188 K211.5 K230.9 K
Slightly volatile
Other Assets27.4 K28.9 K376.5 K
Pretty Stable
Long Term Debt126.9 K133.6 K1.8 M
Pretty Stable
Property Plant Equipment228.6 K217.7 K88.4 K
Slightly volatile
Long Term Debt Total104.1 K109.5 K2.2 M
Slightly volatile
Capital Surpluse57.5 M100.4 M60.3 M
Slightly volatile
Short and Long Term Debt118.1 K124.3 K3.4 M
Slightly volatile
Deferred Long Term Liabilities2.2 M4.5 M2.3 M
Slightly volatile
Deferred Long Term Asset Charges3.1 M3.5 M3.8 M
Slightly volatile
Capital Stock3.1 K3.3 K144.8 K
Slightly volatile

Zivo Bioscience Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense25.1 K26.4 K1.3 M
Pretty Stable
Other Operating Expenses16.3 M15.5 M6.9 M
Slightly volatile
Total Operating Expenses16.2 M15.4 M6.9 M
Slightly volatile
Selling General Administrative12.4 M11.8 M4.9 M
Slightly volatile
Research Development3.8 M3.6 MM
Slightly volatile
Selling And Marketing Expenses120.3 K178.8 K179.7 K
Pretty Stable
Non Recurring2.4 M3.3 M2.3 M
Slightly volatile

Zivo Bioscience Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow1.9 M1.8 M1.1 M
Slightly volatile
Begin Period Cash Flow299.8 K315.5 K828.7 K
Slightly volatile
Stock Based Compensation11.4 M10.9 M2.9 M
Slightly volatile
Change Receivables86.4 K97.2 K106.1 K
Slightly volatile
Issuance Of Capital Stock4.9 M6.4 M4.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio563536207
Very volatile
Days Sales Outstanding5.615.945.7883
Slightly volatile
Average Payables582.9 K515.3 K811.8 K
Very volatile
Stock Based Compensation To Revenue56.9454.2352.3478
Very volatile
Capex To Depreciation12.1911.6110.5143
Slightly volatile
EV To Sales553527344
Pretty Stable
Inventory Turnover5.365.654.7056
Slightly volatile
Days Of Inventory On Hand81.2385.51153
Slightly volatile
Payables Turnover0.310.170.0629
Slightly volatile
Sales General And Administrative To Revenue62.0258.82178
Very volatile
Average Inventory6.3 K6.6 KK
Pretty Stable
Research And Ddevelopement To Revenue20.8317.95114
Slightly volatile
Capex To Revenue0.04960.05220.0538
Slightly volatile
Cash Per Share0.730.411.0221
Pretty Stable
Days Payables Outstanding3.5 K2.3 K19.6 K
Pretty Stable
Intangibles To Total Assets0.60.580.539
Slightly volatile
Current Ratio0.760.720.4155
Slightly volatile
Receivables Turnover67.264.017.7393
Slightly volatile
Capex Per Share1.341.281.1606
Slightly volatile
Average Receivables1.6 K1.7 K15.7 K
Slightly volatile
Revenue Per Share0.05040.0530.0301
Very volatile
Debt To Assets0.130.1414.4592
Slightly volatile
Operating Cycle5.615.9127
Slightly volatile
Days Of Payables Outstanding3.5 K2.3 K19.6 K
Pretty Stable
Quick Ratio0.760.720.4063
Slightly volatile
Net Income Per E B T0.820.921.1118
Slightly volatile
Cash Ratio0.710.680.385
Slightly volatile
Days Of Inventory Outstanding81.2385.51153
Slightly volatile
Days Of Sales Outstanding5.615.945.7883
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.831.01.0693
Pretty Stable
Fixed Asset Turnover0.310.320.7289
Slightly volatile
Debt Ratio0.130.1414.4592
Slightly volatile
Price Sales Ratio563536207
Very volatile
Asset Turnover0.10.110.0981
Slightly volatile

Zivo Bioscience Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.5 M1.8 MM
Slightly volatile
Enterprise Value1.8 M1.9 M6.1 M
Very volatile

Zivo Fundamental Market Drivers

Zivo Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Zivo Bioscience Financial Statements

Zivo Bioscience investors utilize fundamental indicators, such as revenue or net income, to predict how Zivo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-276 K-262.2 K
Total Revenue141.5 K148.6 K
Cost Of Revenue97.4 K56.4 K
Stock Based Compensation To Revenue 54.23  56.94 
Sales General And Administrative To Revenue 58.82  62.02 
Research And Ddevelopement To Revenue 17.95  20.83 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(97.74)(102.62)

Pair Trading with Zivo Bioscience

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zivo Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zivo Bioscience will appreciate offsetting losses from the drop in the long position's value.

Moving against Zivo Stock

  0.74KVUE Kenvue Inc Earnings Call TodayPairCorr
  0.72NATR Natures Sunshine ProductsPairCorr
  0.7HLF Herbalife Nutrition Sell-off TrendPairCorr
  0.59NAII Natural AlternativesPairCorr
  0.53EL Estee Lauder Companies Earnings Call TodayPairCorr
The ability to find closely correlated positions to Zivo Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zivo Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zivo Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zivo Bioscience to buy it.
The correlation of Zivo Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zivo Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zivo Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zivo Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Zivo Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zivo Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zivo Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zivo Bioscience Stock:
Check out the analysis of Zivo Bioscience Correlation against competitors.
To learn how to invest in Zivo Stock, please use our How to Invest in Zivo Bioscience guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Personal Care Products sector continue expanding? Could Zivo diversify its offerings? Factors like these will boost the valuation of Zivo Bioscience. Anticipated expansion of Zivo directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Zivo Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.18)
Revenue Per Share
0.056
Quarterly Revenue Growth
1.083
Return On Assets
(10.02)
Return On Equity
(39.56)
Understanding Zivo Bioscience requires distinguishing between market price and book value, where the latter reflects Zivo's accounting equity. The concept of intrinsic value - what Zivo Bioscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Zivo Bioscience's price substantially above or below its fundamental value.
Please note, there is a significant difference between Zivo Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zivo Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Zivo Bioscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.